| | english | español | français |
Go to record ID

  Home|Finding Information|Record details   Printer-friendly version

Risk Assessment
Record information and status
Record ID
115731
Status
Published
Date of creation
2020-10-06 08:44 UTC (sean.simpkins@defra.gov.uk)
Date of last update
2020-10-20 08:27 UTC (sean.simpkins@defra.gov.uk)
Date of publication
2020-10-20 11:42 UTC (sue.goligher@defra.gov.uk)

General Information
Country
  • United Kingdom of Great Britain and Northern Ireland
Title of risk assessment
Risk Analysis-OX513A Aedes aegypti mosquito for potential release on the Cayman Islands (Grand Cayman)
Date of the risk assessment
2009-10-01
Competent National Authority(ies) responsible for the risk assessment
Department for Environment, Food and Rural Affairs
2nd Floor
Seacole Building
Marsham Street
London
United Kingdom of Great Britain and Northern Ireland, SW1P 4DF
Phone:+ 44 20 806 4121
Email:gm-regulation@defra.gsi.gov.uk,sue.goligher@defra.gov.uk
Risk assessment details
Living modified organism
Dominant lethal Aedes aegypti mosquito
Dr. Lee Han Lim Conditional lethality Selectable marker genes and reporter genes
Show detection method(s)
Scope of the risk assessment
Risk assessment report / Summary
Methodology and points to consider
Potential adverse effects identified in the risk assessment
Ecological niche replacement and alteration of food chains or webs by the removal of Aedes aegypti from the environment. The potential for genetically modified A. aegypti to be less susceptible to insecticides.
Likelihood that the potential adverse effects will be realized
The proposed release is short in duration, limited in scope and the A. aegypti strain cannot establish due the self-limiting genetic lethality, such that more than 95% of the progeny will die.
Possible consequences:
Ecological niche replacement and potential increase in disease transmission by the secondary vector of dengue, A. albopictus. Transfer of reduced insecticide susceptibility to the wild mosquito population.
Estimation of the overall risk
The limited duration of the trial means there are not likely to be any pathogenic or ecologically disruptive effects.
Recommendation(s)
The risks are acceptable due to the scope of the limited duration trial and the self-limiting genetic lethality of the genetically modified mosquito.
Receiving environment(s) considered
This is discussed in the risk assessment document, but briefly the trial is to be confined to one island (Grand Cayman) and the target ecosystem is urban due to the species of target organism (A. aegypti).
LMO detection and identification methods proposed
The LMO produces a fluorescent marker (DsRed) allowing accurate discrimination from wild type. The Transgenic construct can also be reliably detected by DNA-sequence based methods including the Polymerase chain reaction
Additional Information
Other relevant website address or attached documents

Records referencing this document (1)
IDDescription
1record(s) found
Country's Decision or any other Communication1 record